As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis (PrEP) medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.
Approved in June 2025, Yeztugo (lenacapavir) is a twice-yearly injectable PrEP. The One2PrEP campaign uses a reimagined version of Ciara’s hit “1, 2 Step” to destigmatize HIV prevention. Gilead is ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results